AR and lung carcinoma: Conversely, AR reduction, achieved by introducing AR-shRNA (shAR) (Fig. 1H and N), resulted in a significant addition in lung cancer cell invasion and decreased cisplatin response of H1299 and A549 cells (Fig. 1I, J, O, P).